Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa

Plain-language summary

This study evaluates the gene therapy FT-002 in people with X-linked retinitis pigmentosa associated with RPGR gene variants. It enrolls males aged 8 to 45 with this diagnosis. It is in Early Phase 1 and is currently recruiting.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Early Phase 1

Status

Recruiting

Sponsor

Frontera Therapeutics

Intervention

FT-002

Start date

2/1/2023

Estimated completion

11/1/2027

Countries

China

Related genes

Locations

• Beijing, China
• Shanghai, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1.Subjects that are willing and able to follow study procedures; 2.Males aged 8-45 years old at the time of signing the Informed Consent Form; 4.Subjects who are confirmed with variants of RPGR ;

Exclusion Criteria:

1.Have other retinal degenerative diseases, such as retinal degeneration caused by other known Inherited retinal disease gene variants or previously received an gene therapy product.